Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012 (2012), Article ID 683065, 10 pages
http://dx.doi.org/10.1155/2012/683065
Research Article

In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against Acute Myeloid Leukemia

1INSERM U590/Equipe Cytokines et Cancer, Centre Léon Bérard, 69373 Lyon Cedex 08, France
2Centro Ricerca “M. Tettamanti”, Clinica Pediatrica Università Milano-Bicocca, Ospedale San Gerardo, Via Donizetti 106, 20052 Monza, Italy
3Pediatrics, Cell Therapy Section, The University of Texas MD Anderson Cancer Center, Houston, 77030 TX, USA
4Pediatric Hematology-Oncology, Center for Cell and Gene Therapy, Texas Children's Cancer Center, Baylor College of Medicine, Houston, 77030 TX, USA
5UCB Celltech, 216 Bath Road, Slough, Berkshire SL1 3WE, UK
6Pediatric Hematology-Oncology, Université Claude Bernard Lyon I, 69373 Lyon Cedex 08, France

Received 19 August 2011; Accepted 5 October 2011

Academic Editor: J. F. San Miguel

Copyright © 2012 A. Dutour et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. M. Kowolik, M. S. Topp, S. Gonzalez et al., “CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells,” Cancer Research, vol. 66, no. 22, pp. 10995–11004, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Pieper, C. Scheffold, S. Duwe et al., “Immunotherapy of B-cell malignancies with genetically engineered human CD8+ natural killer T cells,” Leukemia, vol. 20, no. 4, pp. 729–732, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Ahmed, M. Ratnayake, B. Savoldo et al., “Regression of experimental medulloblastoma following transfer of HER2-specific T cells,” Cancer Research, vol. 67, no. 12, pp. 5957–5964, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Vera, B. Savoldo, S. Vigouroux et al., “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood, vol. 108, no. 12, pp. 3890–3897, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. G. C. Faulkner, A. S. Krajewski, and D. H. Crawford, “The ins and outs of EBV infection,” Trends in Microbiology, vol. 8, no. 4, pp. 185–189, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Bollard, S. Gottschalk, A. M. Leen et al., “Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer,” Blood, vol. 110, no. 8, pp. 2838–2845, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. E. Heslop, K. S. Slobod, M. A. Pule et al., “Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients,” Blood, vol. 115, no. 5, pp. 925–935, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. Pule, B. Savoldo, G. D. Myers et al., “Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma,” Nature Medicine, vol. 14, no. 11, pp. 1264–1270, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. J. McMillan and P. R. Crocker, “CD33-related sialic-acid-binding immunoglobulin-like lectins in health and disease,” Carbohydrate Research, vol. 343, no. 12, pp. 2050–2056, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. J. Pearce, D. Taussig, K. Zibara et al., “AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML,” Blood, vol. 107, no. 3, pp. 1166–1173, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Nakahata and N. Okumura, “Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers,” Leukemia and Lymphoma, vol. 13, no. 5-6, pp. 401–409, 1994. View at Google Scholar · View at Scopus
  12. D. C. Taussig, D. J. Pearce, C. Simpson et al., “Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia,” Blood, vol. 106, no. 13, pp. 4086–4092, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Stasi, “Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia,” Expert Opinion on Biological Therapy, vol. 8, no. 4, pp. 527–540, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Pagano, L. Fianchi, M. Caira, S. Rutella, and G. Leone, “The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients,” Oncogene, vol. 26, no. 25, pp. 3679–3690, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. M. L. Linenberger, “CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance,” Leukemia, vol. 19, no. 2, pp. 176–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Cianfriglia, A. Mallano, A. Ascione, and M. L. Dupuis, “Multidrug transporter proteins and cellular factors involved in free and mAb linked calicheamicin-γ1 (gentuzumab ozogamicin, GO) resistance and in the selection of GO resistant variants of the HL60 AML cell line,” International Journal of Oncology, vol. 36, no. 6, pp. 1513–1520, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Bonini, A. Bondanza, S. K. Perna et al., “The suicide gene therapy challenge: how to improve a successful gene therapy approach,” Molecular Therapy, vol. 15, no. 7, pp. 1248–1252, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. V. Marin, I. Pizzitola, V. Agostoni et al., “Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors,” Haematologica, vol. 95, no. 12, pp. 2144–2152, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. C. A. Smith, C. Y. C. Ng, H. E. Heslop et al., “Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease,” Journal of Hematotherapy, vol. 4, no. 2, pp. 73–79, 1995. View at Google Scholar · View at Scopus
  20. B. Savoldo, J. Goss, Z. Liu et al., “Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients,” Transplantation, vol. 72, no. 6, pp. 1078–1086, 2001. View at Google Scholar · View at Scopus
  21. B. Savoldo, C. M. Rooney, A. Di Stasi et al., “Epstein Barr virus-specific cytotoxic T lymphocytes expressing the anti-CD30ζ artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease,” Blood, vol. 110, no. 7, pp. 2620–2630, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. C. Yang, S. Hillinger, K. Riedl et al., “Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity,” Clinical Cancer Research, vol. 10, no. 8, pp. 2891–2901, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Quintarelli, J. F. Vera, B. Savoldo et al., “Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes,” Blood, vol. 110, no. 8, pp. 2793–2802, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Gattinoni, D. J. Powell Jr., S. A. Rosenberg, and N. P. Restifo, “Adoptive immunotherapy for cancer: building on success,” Nature Reviews Immunology, vol. 6, no. 5, pp. 383–393, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Wrzesinski, C. M. Paulos, A. Kaiser et al., “Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells,” Journal of Immunotherapy, vol. 33, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. C. Taussig, F. Miraki-Moud, F. Anjos-Afonso et al., “Anti-CD38 antibody—mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells,” Blood, vol. 112, no. 3, pp. 568–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Zhao, E. Moon, C. Carpenito et al., “Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor,” Cancer Research, vol. 70, no. 22, pp. 9053–9061, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Robak and A. Wierzbowska, “Current and emerging therapies for acute myeloid leukemia,” Clinical Therapeutics, vol. 31, no. 2, pp. 2349–2370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. B. A. Guinn, A. Mohamedali, N. S. B. Thomas, and K. I. Mills, “Immunotherapy of myeloid leukaemia,” Cancer Immunology, Immunotherapy, vol. 56, no. 7, pp. 943–957, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. D. J. Pearce, D. C. Taussig, and D. Bonnet, “Implications of the expression of myeloid markers on normal and leukemic stem cells,” Cell Cycle, vol. 5, no. 3, pp. 271–273, 2006. View at Google Scholar · View at Scopus
  31. J. N. Kochenderfer, W. H. Wilson, J. E. Janik et al., “Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19,” Blood, vol. 116, no. 20, pp. 4099–4102, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. B. Kohn, G. Dotti, R. Brentjens et al., “CARs on track in the clinic,” Molecular Therapy, vol. 19, no. 3, pp. 432–438, 2011. View at Publisher · View at Google Scholar